Skip to content

Postconditioning Rotterdam Trial

Additional treatment to primary PCI: effects of ischemic postconditioning after thrombectomy

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
NL-OMON
Registry ID
NL-OMON26072
Enrollment
72
Registered
2013-06-14
Start date
2013-05-17
Completion date
Unknown
Last updated
2024-02-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

myocardial infarction, primairy PCI, STEMI, thrombectmy, postconditioning, MRI

Interventions

Primairy PCI including thrombectomy with or without ischemic postconditioning. In the ischemic postconditioning group, directly after successful thrombectomy within one minute of reflow after opening

Sponsors

Felix Zijlstra, MD, PhD and Olivier Manintveld, MD, PhD (Thoraxcenter, Erasmus MC, Rotterdam, the Netherlands)
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Patients are included in the study when written informed consent is given. Consecutive patients as defined above are screened for inclusion in the trial. The eligibility criteria consist of the following: 1. Delay between onset of chest pain and PCI ≤ 6 hours in case of inferiolateral wall infarction and ≤ 12 hours in case of anterior wall infarction; 2. An occluded infarct related artery must be demonstrated (TIMI-flow 0-1).

Exclusion criteria

Exclusion criteria: 1. Younger than 18 or older than 75 years of age; 2. Cardiogenic shock defined as sustained systolic blood pressure &#8804; 80 mmHg despite fluid hydration and/or the inability to discontinue vasopressors in less than 1 hour before; 3. Post cardiac resuscitation; 4. Thrombolytic therapy in the previous week; 5. Myocardial infarction biomarkers at admission >5 times the upper limit of normal since this implies longer lasting myocardial infarction; 6. TIMI-flow >1 before intervention or TIMI-flow <2 after initial balloon inflation; 7. Significant collateral blood flow to the distal vasculature of the occluded vessel; 8. An extended myocardial infarction, as evidenced by a new episode of chest pain with new ST-segment elevations and a new CK / CK-MB peak; 9. Documented hospital admission for heart failure; 10. Known pre-existent left ventricular dysfunction measured by any technique (ejection fraction < 45% prior to current admission for myocardial infarction); 11. History of known previous myocardial infarction; 12. Prior coronary artery bypass grafting; 13. Moderate to severe cardiac valve disease; 14. Known cardiomyopathy; 15. Congenital cardiac disease; 16. Blood transfusion in the previous 24 hours; 17. Stroke or transient ischemic attack within the previous 24 hours; 18. Any contraindication for Magnetic Resonance Imaging i.e.: • pacemaker • cerebrovascular clips • claustrophobia 19. Chronic use of anti-inflammatory medication, except for the use of NSAIDs (non-steroidal anti-inflammatory drugs); 20. Serious known concomitant disease with a life expectancy of less than one year; 21. Follow-up impossible (no fixed abode, etc); 22. Previous participation in this study or any other trial within the previous 30 days.

Design outcomes

Primary

MeasureTime frame
Difference of myocardial infarct size between treatment groups measured on delayed enhance (DE) MRI at 3 months.

Secondary

MeasureTime frame
The difference between treatment groups in • Myocardial infarct size as measured by serum CK release during the first 72 hours after PCI. • ST segment resolution after PCI at time of return to the coronary care unit, at 60 and 90 minutes. • Salvaged area measured as the area at risk on T2 weighed MRI minus the final infarct size on DE MRI. • Index of microvascular resistance, true resistance and fractional flow reserve after primairy PCI • Regional myocardial function based on a MRI segmental analysis at 3 months. • Global left ventricular ejection fraction at 3 months measured by MRI. • Microvascular obstruction measured by MRI at 3-5 days after PCI. • Blush grade measured at primairy PCI. • The occurrence within 3 months of a Major Adverse Cardiac Event defined as cardiac death, myocardial infarction, coronary bypass grafting, or a repeat percutaneous intervention of the culprit lesion. • Concentrations of chemokines (including NT-pro-BNP) and cytokines at 3 months relative to 24 hours. • Creatinine at admission, day 1, 2, 3 and 4.

Contacts

Public ContactOliver C. Manintveld,

Thoraxcenter, room Ba-575 Erasmus University Medical Center ‘s-Gravendijkwal 230

o.manintveld@erasmusmc.nl+31 (0)10 703 5407

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)